Approximately 90% of CRC patients harbor loss-of-function mutations in the gene that encodes adenomatous polyposis coli (APC) [17,18], a mutation that promotes the nuclear accumulation of the Wnt effector β-catenin and leads to the clonal expansion of ISCs and CRC initiation [17,19,20]. Here, APC is linked to colorectal carcinoma.